Engflag

Ceftibuten

Quick links to important sections

Ceftibuten

Ceftibuten_DE

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ceftibuten

Property Description
Active ingredient Ceftibuten
Form Capsule, Oral Suspension
Pharmacological class Third-Generation Cephalosporin
General purpose Resolving bacterial invasions
Origin Semisynthetic

Ceftibuten is a semisynthetic β-Lactam antibiotic used to resolve various types of bacterial infections. As a single-ingredient product, its medicinal identity is defined entirely by the Ceftibuten active agent, which functions as a targeted means of eliminating susceptible pathogens.

What Type of Antibiotic is Ceftibuten?

Ceftibuten is classified as a Third-Generation Cephalosporin, a specific pharmacological class of antibacterial compounds.

This classification places it within the larger family of β-Lactam antibiotics, defined by a common chemical ring structure essential for its function. Third-generation agents are characterized by their increased efficacy against many Gram-negative bacteria and greater stability against common bacterial resistance mechanisms compared to agents from earlier cephalosporin generations. The key differentiator for Ceftibuten, when contrasted with similar oral cephalosporins, is its high bioavailability, confirming reliable systemic absorption when taken orally. Ceftibuten is a prescription-only medication, reflecting its potent and targeted anti-infective purpose.

Composition, Available Forms, and General Purpose

The active ingredient in this medication is Ceftibuten (often present as the dihydrate), which is responsible for the entire therapeutic effect.

Ceftibuten is available for oral administration in two primary dosage forms: capsules for adult patients and an oral suspension typically utilizing an aqueous-based vehicle. The suspension formulation is distinctively geared towards pediatric or adult patients unable to swallow solid medication, providing flexibility in patient care. The general purpose of the drug is achieved through its bactericidal (bacteria-killing) action, where it actively works by interfering with the synthesis of the bacterial cell wall, causing the pathogen to lose its structural integrity and die. This targeted mechanism enables the medication to effectively combat and resolve bacterial invasions throughout the body. The drug's intended use is to treat infections caused by specific susceptible bacteria.

What side effects are possible with Ceftibuten?

Possible Side Effects and Safety Information

Ceftibuten's officially documented safety profile classifies adverse reactions based on their frequency of occurrence, primarily affecting the gastrointestinal and nervous systems. The most common effects, documented in regulatory sources to occur in 1% to 10% of patients, include diarrhea, nausea, and headache. Other common effects include dyspepsia, abdominal pain, vomiting, dizziness, and changes in routine laboratory values such as temporary increases in liver enzymes (ALT, Bilirubin) or blood cell counts.

Serious Adverse Reactions

The regulatory label documents the potential for rare but serious adverse reactions, including severe hypersensitivity responses such as Anaphylaxis, which is a risk common to the beta-lactam antibiotic class. Clinically significant gastrointestinal risks include Pseudomembranous Colitis and Clostridium difficile-associated diarrhea (CDAD), which may occur during or after treatment. Severe reactions involving the central nervous system, such as seizures (convulsions), have been reported, particularly in patients with pre-existing renal impairment whose dosage was not adequately adjusted.

Safety Considerations and Restrictions

Ceftibuten is contraindicated in individuals with known hypersensitivity to the active ingredient or to any other beta-lactam antibiotics, including penicillins, due to the risk of cross-allergenicity. Dosage modification is officially required for patients with moderate to severe renal impairment to prevent elevated drug concentrations. Additionally, official documents state that prolonged use of the medication may lead to superinfection by non-susceptible organisms. The medicine may also cause a positive direct Coombs' Test and interfere with certain urinary glucose tests.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information addresses specific manifestations and required emergency actions in the event of Ceftibuten overdosage.

Documented Overdose Manifestations and Risks

Feature Official Regulatory Statement
Documented Manifestations The primary neurological sign associated with overdosage is the potential for seizures (convulsions), a known risk for the cephalosporin class of antibiotics.
Physiological System Affected The Central Nervous System (CNS) is the primary system noted for acute toxic effects.
Population-Specific Note Patients with renal impairment face an increased risk of drug accumulation and high plasma concentrations, which may predispose them to increased toxicity, including seizures.

Official Emergency Actions Required

Regulatory guidance explicitly defines when immediate medical help must be sought for Ceftibuten overdosage:

  • Seek immediate medical attention or call the poison control helpline if an overdose is suspected.
  • Immediately call emergency services (e.g., 911) if the individual has severe signs, including collapse, a seizure, trouble breathing, or inability to be awakened.

Supportive Management

  • No specific pharmacological antidote is documented in the official prescribing information.
  • The procedure of hemodialysis is documented as effective for drug removal, with studies showing it removes approximately 65% of the drug from the bloodstream within a typical session, indicating its utility in managing high drug concentrations.

Therapeutic Uses of Ceftibuten

What Ceftibuten Treats: Main Uses and Benefits

Ceftibuten is an antibiotic used for managing symptoms associated with acute bacterial infections, providing supportive relief when symptoms are related to infectious states. It is commonly prescribed for conditions involving symptoms of the ears, throat, tonsils, and bronchial tubes.

Therapeutic Applications and Symptom Support

The medication is applicable within therapeutic areas involving acute or disruptive symptom patterns, such as acute otitis media, pharyngitis, tonsillitis, and acute exacerbations of chronic bronchitis. It is also considered relevant when symptoms are driven by an uncomplicated bacterial urinary tract infection (UTI).

This medication helps address symptom clusters that may become intense or disruptive, supporting patients during difficult episodes by easing distress. The primary role is to help manage symptoms related to physical discomfort and inflammatory states.

“The general application is relevant in clinical settings that involve acute or unstable symptom patterns.”

Clinical Scenario and Patient Benefit

Ceftibuten is commonly used in outpatient settings when short-term symptomatic assistance is needed. It is applied in addressing symptoms that become more disruptive during flare-ups, which may assist with maintaining functional stability during periods of heightened symptoms. This application generally contributes to easing the overall symptom load.

Quick Fact: Supports Management of Inflammatory Discomfort

Regulatory References

  1. NIH MedlinePlus overview of Ceftibuten

Eligibility and Restrictions for Use

Ceftibuten's eligibility profile is strictly defined by regulatory documents, identifying absolute exclusions and populations requiring conditional use.

Populations Excluded or Restricted

Classification Population/Condition
Contraindicated Individuals with a known hypersensitivity (allergy) to Ceftibuten or to the cephalosporin class of antibiotics.
Use Not Established Infants under 6 months of age.
Requires Restriction Patients with moderate to severe renal impairment (kidney disease).

Age and Physiological Status

Ceftibuten is approved for use in children aged 6 months and older, as well as adults. For patients with compromised kidney function, use is restricted and requires a mandatory dose adjustment because the drug is primarily cleared by the kidneys. For pregnant women, Ceftibuten is generally classified as allowed only if clearly needed, given the lack of adequate human-controlled studies (FDA Pregnancy Category B). During breastfeeding, use is generally considered acceptable as only low levels of the drug are excreted into human milk.

What should I know about interactions with other medicines?

Ceftibuten's interaction profile is categorized by its official effect on co-administered substances or its own systemic exposure. Pharmacodynamic restrictions establish formally contraindicated combinations with live vaccines (e.g., Cholera, Typhoid, BCG) and live bacterial products due to the potential for pharmacodynamic antagonism.

The official profile notes that co-administration with Oral Anticoagulants (Vitamin K Antagonists) may increase the anticoagulant effects, carrying a documented risk of bleeding. Combination with Aminoglycosides is also associated with an increased risk of nephrotoxicity.

Pharmacokinetic interactions formally define effects on drug concentration. Probenecid decreases renal clearance, an interaction that results in increased Ceftibuten plasma concentration. Ranitidine officially increases Ceftibuten C max by 23% for the capsule form. Ceftibuten officially decreases the level of oral contraceptives by altering intestinal flora.

Timing-based requirements are mandatory for absorption management. The oral suspension form must be taken on an empty stomach (separated by at least two hours before or one hour after a meal) due to food officially reducing its absorption. Supplements containing Zinc or Multivitamins with Minerals must be separated by at least three hours to avoid absorption interference. In patients with renal dysfunction, decreased clearance results in increased systemic exposure.

Mechanism of Action

Molecular Targeting of Bacterial Cell Wall Builders

Ceftibuten acts as an irreversible inhibitor of essential bacterial enzymes called Penicillin-Binding Proteins (PBPs), particularly PBP 3. By covalently binding to these enzymes, the drug prevents them from completing the final step—transpeptidation—in the construction of the bacterial cell wall. This mechanism focuses on the pathogen's structure and cell wall machinery.

Mechanistic Cascade and Bactericidal Lytic Action

The molecular inhibition initiates a rapid mechanistic cascade. The halt in cell wall construction leaves the bacterial cell structurally compromised and unable to withstand the high internal osmotic pressure , leading to the rapid lysis (bursting) and subsequent bactericidal effect.

️ Boundaries of Mechanistic Effectiveness

This cluster addresses mechanistic constraints: the action is overridden when bacteria structurally alter their PBP targets or produce specific, inactivating cephalosporinase enzymes. The drug is susceptible to hydrolysis by these enzymes, which prevents the drug from reaching its intended target and blocking the cell wall pathway.

Dosage and Administration Information

Ceftibuten is administered exclusively via the oral route and is available in two primary forms: a 400 mg capsule and a powder for oral suspension (available in 90 mg/5 mL and 180 mg/5 mL concentrations after reconstitution). The standard regimen for approved uses requires dosing once daily (every 24 hours) for a typical course duration of 10 days.

Standard and Adjusted Dosing Regimens

The standard dose for adults and pediatric patients weighing at least 45 kg is 400 mg once daily. For children 6 months to 11 years, the dose is weight-based at 9 mg/kg once daily, with a maximum daily limit of 400 mg. Dosing is not established for infants younger than 6 months. Dosage adjustment is not required for patients with hepatic impairment.

The following regimens are required for patients with impaired kidney function:

Renal Function (Creatinine Clearance) Adult Dose (at least 12 years) Pediatric Dose (6 mos – 11 yrs)
30–49 mL/min 200 mg once daily 4.5 mg/kg once daily
5–29 mL/min 100 mg once daily 2.25 mg/kg once daily

Patients undergoing hemodialysis receive a single 400 mg dose (or 9 mg/kg) at the completion of the dialysis session.

Administration Timing and Procedure

To optimize administration, the oral suspension must be taken separated from food—specifically at least 2 hours before or 1 hour after a meal. The capsule formulation may be taken without regard to food. If a once-daily dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the subsequent scheduled dose, the missed dose must be skipped, and the regular dosing schedule should be resumed without taking a double dose.

Recent Clinical Evidence

Ceftibuten: Recent Clinical Evidence

Evidence by Condition Studied

The research base for Ceftibuten is characterized by short-term Randomized Controlled Trials (RCTs) and comparative studies used to evaluate its application in several acute infections.

For Acute Otitis Media (AOM), studies primarily involved infants and children. Researchers focused on measuring outcomes related to how symptoms change over time, specifically assessing Clinical cure rates and Bacteriological eradication. Findings describe patterns observed when compared against other antibiotics utilized as comparators. Similarly, trials for Pharyngitis and Tonsillitis in children and adolescents monitored these same outcomes.

In Acute Exacerbations of Chronic Bronchitis (AECB), studies in adults monitored outcomes related to physical discomfort and the elimination of bacterial isolates. Data show patterns related to variability in clinical success rates depending on the isolated pathogen. Research also examined the drug's application in both uncomplicated and complicated Urinary Tract Infections (UTIs) in adult populations.

Limitations and Uncertainties in Research

Clinical trials generally focused on short-term symptom changes with limited follow-up durations extending only a few weeks post-treatment. There is limited information for long-term outcomes, meaning the research does not fully determine functional stability or recurrence prevention after the study period.

The majority of existing research is comprised of comparative trials against older antibiotics, and comparative evidence against the most current treatments and resistance profiles is limited. Data for certain complex patient groups remain insufficient. The certainty remains low regarding the drug’s activity against specific multi-drug-resistant organisms, such as ESBL-producing strains, which have become more common since the time of the main trials.

Key Studies & References Ceftibuten (Oral Route) Overview

Frequently Asked Questions (FAQ)

Common questions about Ceftibuten (FAQ)

Q: What are the brand names for Ceftibuten?

A: The active ingredient Ceftibuten has been marketed in the United States under the brand name CEDAX. Brand names for medications may vary depending on the country or region.

Q: What is the specific maximum daily dose for a child under the age of 12?

A: Official prescribing information indicates the maximum daily limit for children between 6 months and 12 years of age. Doses for children are typically weight-based, and the maximum total dose should not be exceeded. Specific dosing details are determined by a healthcare professional.

Q: How long after starting the medication should I expect to feel better or see an improvement in my symptoms?

A: Patient education materials suggest that improvement in symptoms may begin within the first few days of starting treatment. If symptoms do not improve or if they worsen after this initial period, contact with a healthcare provider is recommended.

Q: How does Ceftibuten work in my body to help resolve the infection?

A: Ceftibuten is a bactericidal antibiotic, meaning its function is to actively kill the susceptible bacteria causing the infection. It achieves this by interfering with the synthesis of the bacterial cell wall, which causes the pathogen to lose its structural integrity.

Q: What should I do if I forget to take my daily dose?

A: Official administration instructions address this situation. If a dose is missed, taking it as soon as it is remembered is indicated by the product information. However, if the time is very close to the next scheduled dose, the instruction is to skip the missed dose entirely and resume the regular schedule. Taking a double dose to compensate for a missed one is explicitly not recommended.

Q: Is Ceftibuten known to interact with any other medications?

A: Yes, official labeling documents several important drug interactions. For example, Ceftibuten may increase the effects of oral anticoagulants, which are blood-thinning medicines. The label also documents interactions with Aminoglycosides, which may carry an increased risk of nephrotoxicity (kidney issues). Additionally, it may decrease the effectiveness of oral contraceptives.

How should Ceftibuten be stored and disposed of?

How to Store and Dispose of Ceftibuten? (Regulatory Guidelines)

Ceftibuten storage requirements are set by regulatory agencies to maintain stability, differing by dosage form.

Storage Requirements

Dosage Form Temperature Requirement Stability Constraint
Capsules/Dry Powder Controlled Room Temp (2 C–25 C) Protect from freezing, heat, moisture, and light.
Reconstituted Suspension Refrigerated (2 C–8 C) Discard after 14 days; keep tightly closed.

All forms must be stored out of the sight and reach of children.

Disposal

Outdated or unused medicine must not be kept. Individuals should ask a healthcare professional or pharmacist for specific disposal guidance. If no drug take-back program is available, the FDA advises mixing the unused medicine with an undesirable substance, sealing it in a bag, and placing it in the trash. Ceftibuten should not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Ceftibuten found in:

A-Z Index: